This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

KaloBios Appoints Harry Lam, Ph.D. As Head Of Manufacturing





SOUTH SAN FRANCISCO, Calif., Jan. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he ultimately served as Global Head of Contract Manufacturing Operations, Commercial Drug Substance, for the Roche Group.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

" Harry Lam joins KaloBios with a wealth of experience in building and leading technical operations and manufacturing teams on a global basis, including the global oversight of drug substance contract manufacturing for all of the Roche Group's products," said David Pritchard, Kalobios' President and Chief Executive Officer. "His experience in directing science and technology on a global basis for drug substance manufacturing will be especially pertinent to KaloBios as we continue to advance the development of our patient-targeted antibody therapeutics towards commercialization."

Dr. Lam was most recently Vice President and Head of Manufacturing for Shire Regenerative Medicine. From 1996 to March 2013, he was an employee of Genentech where he held a variety of increasingly responsible positions related to manufacturing operations, manufacturing science and technology and fermentation operations. In addition to his roles as Global Head of Contract Manufacturing Operations, Commercial Drug Substance (2012-2013), and Senior Director, Global Biologics Drug Substance Manufacturing Science & Technology (2010-2012), during his time at Genentech, Dr. Lam led and managed the technology and operations groups in the commissioning, qualification, tech transfer, process validation, and licensure of  Genentech's bacterial production facility in Singapore (2007-2010). He received his Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute and his B.Sc. in Chemical Engineering from the University of Birmingham, UK.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs